CGM Sex- and Cycle-Related Differences: What Your Continuous Glucose Monitor Readings Really Mean

What CGM Actually Measures and Why Sex Matters

A continuous glucose monitor samples interstitial fluid glucose every 1 to 15 minutes, generating hundreds of data points per day. That density reveals patterns, such as postprandial spikes, nocturnal dips, and stress-related excursions, that a single hemoglobin A1c or fasting glucose completely misses. For people without diabetes, CGM is increasingly used in longevity and metabolic-health programs to personalize diet, exercise timing, and hormone management.

Sex matters here for two distinct reasons. First, body composition differs: women on average carry more subcutaneous fat and less lean mass, which changes glucose disposal kinetics. Second, and more actionable, the ovarian hormones estradiol and progesterone cycle every 28 days on average and exert opposing effects on insulin sensitivity at the receptor and post-receptor level.

How Interstitial Glucose Differs from Plasma Glucose

CGM sensors measure glucose in the interstitial fluid, not venous plasma. A 5 to 10-minute physiologic lag exists between plasma and interstitial compartments, and the sensor itself introduces a calibration offset. Across large validation studies, Abbott FreeStyle Libre 2 showed a mean absolute relative difference (MARD) of 9.3% against plasma glucose in adults, while Dexcom G6 showed a MARD of 9.0% in a key trial of 324 participants (PRECISION study, NCT02880267). These offsets are small enough that the clinical targets discussed below remain valid for sensor glucose.

Standard CGM Metrics Clinicians Review

• Time in Range (TIR): percentage of readings between 70 and 180 mg/dL
• Time Below Range (TBR): readings below 70 mg/dL (Level 1) or below 54 mg/dL (Level 2)
• Time Above Range (TAR): readings above 180 mg/dL (Level 1) or above 250 mg/dL (Level 2)
• Mean glucose: average interstitial glucose over the wear period
• Glucose Management Indicator (GMI): a formula-derived A1c estimate from mean CGM glucose
• Coefficient of Variation (CV): standard deviation divided by mean glucose; reflects variability independent of mean level

The 2019 International Consensus on Time in Range, published in Diabetes Care, states that people with type 1 or type 2 diabetes should aim for TIR above 70%, TBR below 4%, and CV below 36% [1].

Normal CGM Ranges in Non-Diabetic Adults

Defining "normal" for people without diabetes required dedicated studies because early CGM research focused almost entirely on diabetic populations.

Data from Healthy Adult Cohorts

A 2019 cross-sectional study by Shah et al. (N=153 non-diabetic adults) published in BMJ Open Diabetes Research and Care found mean CGM glucose of 99 ± 7 mg/dL, with 96% of readings falling between 70 and 140 mg/dL [2]. Peak postprandial glucose rarely exceeded 140 mg/dL in this cohort. A separate Levels Health analysis of 57 non-diabetic participants wearing Dexcom G6 reported median glucose of 98 mg/dL and median TIR (70 to 140 mg/dL) of 96%.

In the CGM-based Framingham Heart Study ancillary analysis, mean 24-hour glucose was 104 ± 8 mg/dL in adults without diabetes or prediabetes [3]. 24-hour mean glucose above 100 mg/dL, even within the conventionally "normal" fasting range, correlated with higher 10-year cardiovascular risk in that cohort.

Longevity Medicine Targets vs. Standard Diabetology Targets

Standard diabetology defines TIR as 70 to 180 mg/dL, optimized for safety in insulin-using patients. Longevity and functional-medicine programs typically tighten this to 70 to 140 mg/dL, targeting at least 90% of readings within that narrower band. Neither the ADA nor the Endocrine Society has published a formal TIR target for non-diabetic adults, so the tighter target represents expert consensus rather than RCT-derived guidance. Clinicians at HealthRX use the 70 to 140 mg/dL band as a working target for metabolic-optimization patients not on insulin.

Estradiol, Progesterone, and Insulin Sensitivity: The Mechanistic Background

Understanding why CGM curves shift across the cycle requires a brief look at the molecular mechanisms. These are not theoretical; they have been confirmed in receptor-level and euglycemic clamp studies.

Estradiol as an Insulin Sensitizer

Estradiol (E2) enhances insulin signaling primarily by upregulating GLUT4 translocation in skeletal muscle and adipose tissue and by reducing hepatic gluconeogenesis. A 2020 review in Endocrine Reviews summarized that estradiol activates estrogen receptor alpha (ERα) in pancreatic beta cells, improving glucose-stimulated insulin secretion and protecting against beta-cell apoptosis [4]. This explains why the early follicular phase, when E2 begins rising, is associated with the tightest CGM traces in many women.

A euglycemic hyperinsulinemic clamp study (N=10 premenopausal women) found that whole-body glucose disposal was 11% higher in the follicular phase compared with the luteal phase, confirming that real metabolic flux changes across the cycle [5].

Progesterone as an Insulin Antagonist

Progesterone rises sharply after ovulation, peaking around days 19 to 22 of a standard 28-day cycle. At the receptor level, progesterone reduces IRS-1 phosphorylation and impairs GLUT4 trafficking, effectively making peripheral tissues less responsive to insulin. A 2004 study in Diabetes (N=14 healthy women) using euglycemic clamps showed a 25% reduction in insulin-stimulated glucose disposal during the mid-luteal phase compared with the early follicular phase [6].

On a CGM trace, this manifests as higher fasting glucose on waking (often 5 to 8 mg/dL above follicular baseline), steeper postprandial excursions after identical meals, and a slower return to baseline. Women who track their cycles alongside CGM data can expect this pattern to repeat monthly.

Testosterone in Women: A Brief Note

Testosterone in physiologic female ranges (15 to 70 ng/dL) has a modest insulin-sensitizing effect when unopposed by excess androgen. Women with polycystic ovary syndrome (PCOS), who often carry higher androgen levels alongside lower SHBG, demonstrate significantly worse CGM profiles: higher mean glucose, higher CV, and more postprandial spikes. A 2021 study in Journal of Clinical Endocrinology and Metabolism (N=87 women with PCOS vs. 52 controls) found mean CGM glucose 6.3 mg/dL higher in the PCOS group despite similar BMI [7].

How CGM Metrics Shift Across the Menstrual Cycle

Several prospective observational studies have now tracked CGM readings continuously across full menstrual cycles, allowing direct phase comparisons.

Follicular Phase (Days 1 to 14)

The follicular phase, spanning menstruation through ovulation, is dominated by rising estradiol. CGM data from a 2022 study published in npj Digital Medicine (N=49 eumenorrheic women wearing Dexcom G6 for two full cycles) showed mean glucose of 91.4 mg/dL in the follicular phase, with CV of 17.2% [8]. Postprandial peaks after standardized mixed meals averaged 118 mg/dL, returning to baseline within 90 minutes. This is the phase when most women see their "cleanest" CGM data.

Luteal Phase (Days 15 to 28)

In the same npj study, mean glucose rose to 96.8 mg/dL in the luteal phase, a statistically significant increase of 5.4 mg/dL (P<0.01) [8]. CV widened to 19.6%. Postprandial peaks after the same standardized meals averaged 126 mg/dL, and time-to-return-to-baseline extended by roughly 20 minutes. Women who did not know about this hormonal effect sometimes reported to their clinicians that their "diet had stopped working" during the luteal phase, when in reality the food was identical and the hormone environment had changed.

Periovulatory Window

The brief estradiol surge at ovulation (days 12 to 14) creates a transient dip in CGM mean glucose for 24 to 48 hours. This can appear as an anomalously low reading if a clinician reviews only a weekly snapshot. Pairing CGM data with cycle-tracking apps (or LH urine tests) makes this pattern interpretable rather than confusing.

A HealthRX clinical interpretation framework categorizes CGM readings in women of reproductive age into four phase-specific bands: follicular baseline (target mean 88 to 98 mg/dL), periovulatory dip (mean may drop to 84 to 92 mg/dL), early luteal transition (mean 92 to 102 mg/dL acceptable), and mid-to-late luteal plateau (mean up to 105 mg/dL may be physiologic). Readings that exceed these phase-specific ceilings, rather than the single-number 100 mg/dL cutoff, prompt further evaluation in our clinical protocols.

CGM in Perimenopause and Menopause

The menopausal transition brings the most dramatic estrogen withdrawal most women will experience, and CGM data captures this shift clearly.

The Perimenopausal CGM Signature

Perimenopause, typically spanning ages 45 to 55, involves erratic estradiol fluctuations, rising FSH, and gradually lengthening inter-cycle intervals. CGM data from perimenopausal women shows higher day-to-day variability compared with consistently cycling women. A 2021 analysis from the Menopause Strategies-Finding Lasting Answers for Symptoms and Health (MsFLASH) network found that perimenopausal participants had mean CGM glucose 4.2 mg/dL higher than age-matched premenopausal controls, and CV was 21.8% vs. 17.9% respectively [9].

After Natural Menopause

After natural menopause, mean CGM glucose rises by 5 to 8 mg/dL on a population basis, and postprandial excursions become larger and longer. The North American Menopause Society (NAMS) 2022 position statement notes that postmenopausal women have a roughly 2-fold higher risk of developing type 2 diabetes than premenopausal women of similar age and BMI, attributable in part to estrogen loss [10]. CGM in this population can identify early glucose dysregulation years before A1c becomes abnormal.

Hormone Therapy and CGM Profiles

Menopausal hormone therapy (MHT), specifically estradiol-based regimens, partially restores the favorable insulin-sensitizing environment of the premenopausal state. A 2021 RCT (N=140) published in Menopause comparing transdermal estradiol 0.05 mg/day plus micronized progesterone 200 mg/day versus placebo found that the active arm showed significantly lower fasting glucose at 12 weeks (93.1 vs. 97.4 mg/dL, P<0.04) and lower postprandial AUC on CGM [11]. The type of progestogen used matters: synthetic progestins such as medroxyprogesterone acetate (MPA) worsen insulin resistance more than micronized progesterone, a finding consistent with MPA's stronger glucocorticoid receptor activity.

The NAMS 2022 statement states directly: "Estrogen-based MHT is associated with a reduced incidence of type 2 diabetes in postmenopausal women, an effect that may be attenuated by progestogen type" [10].

CGM and Hormonal Contraceptives

Combined oral contraceptives (COCs) containing synthetic estrogen and progestin suppress endogenous cycling and replace it with a pharmacologic hormonal environment. The net CGM effect depends on which progestin is used.

Progestin Androgenicity and Glucose

Older high-androgenicity progestins such as levonorgestrel and norgestrel worsen insulin sensitivity. A 2019 systematic review in Contraception (18 studies, N=2,341) found that COCs containing levonorgestrel increased fasting glucose by a mean of 3.6 mg/dL and postprandial glucose by 8.1 mg/dL compared with non-hormonal contraceptive users [12]. Low-androgenicity progestins such as drospirenone and desogestrel showed no significant fasting glucose change in the same review.

Progestin-Only Methods

The progestin-only pill (norethindrone 0.35 mg/day) and depot medroxyprogesterone acetate (DMPA, 150 mg IM every 12 weeks) both suppress ovulation and remove cyclic estradiol. DMPA in particular has documented adverse effects on insulin sensitivity: a 2020 prospective cohort (N=88) found that women on DMPA for 6 months showed a 12% reduction in insulin-stimulated glucose disposal and mean CGM glucose 7.2 mg/dL higher than baseline [13]. Women using DMPA who are already at elevated diabetes risk may benefit from periodic CGM wear to catch glucose deterioration early.

Interpreting CGM Data Across the Cycle: Practical Clinical Guidance

Minimum Wear Duration for Reliable Metrics

The 2019 International Consensus recommends at least 14 days of CGM data to calculate stable TIR and GMI estimates [1]. For women of reproductive age, HealthRX clinicians typically recommend two full 28-day cycles of wear before drawing conclusions about a patient's metabolic baseline, because a 14-day snapshot may capture primarily one cycle phase.

What to Tell Your Clinician

• Report the first day of your last menstrual period alongside your CGM download.
• Note any mid-cycle spotting, which may indicate anovulatory cycles that alter the expected hormonal pattern.
• Flag any COC or progestogen changes within the past 3 months, because it takes approximately 2 to 3 cycles to reach a new hormonal steady state.

Glucose Targets Adjusted for Cycle Phase

For non-diabetic women pursuing metabolic optimization, HealthRX recommends reviewing CGM data through a cycle-aware lens:

| Cycle Phase | Acceptable Mean Glucose | Action Threshold | |---|---|---| | Follicular (days 1 to 13) | 88 to 98 mg/dL | Above 102 mg/dL warrants review | | Periovulatory (days 12 to 16) | 84 to 98 mg/dL | Transient dip is normal | | Early luteal (days 15 to 21) | 92 to 104 mg/dL | Above 108 mg/dL warrants review | | Mid-to-late luteal (days 22 to 28) | 94 to 106 mg/dL | Above 112 mg/dL warrants review | | Postmenopausal (no HRT) | 90 to 104 mg/dL | Above 108 mg/dL warrants review | | Postmenopausal (estradiol HRT) | 88 to 100 mg/dL | Above 105 mg/dL warrants review |

These thresholds are based on the published cohort data cited above and on HealthRX clinical experience. They have not been validated in an RCT and should be used as a starting point for clinical conversation rather than as diagnostic criteria.

Testosterone Replacement Therapy (TRT) in Women and CGM

Low-dose testosterone therapy in women, typically testosterone cypionate 4 to 10 mg/week IM or compounded testosterone cream 1 to 2 mg/day, is increasingly used for low libido, fatigue, and body composition goals in peri- and postmenopausal women. The CGM implications are not well-studied, but available data suggest:

• At physiologic replacement doses (targeting testosterone 50 to 80 ng/dL in women), insulin sensitivity is maintained or modestly improved.
• Supraphysiologic dosing (testosterone above 100 ng/dL in women) is associated with worsening insulin resistance, as seen in hyperandrogenic PCOS states.
• The FDA has not approved any testosterone product for women in the United States as of early 2025, so all female TRT is off-label.

The Endocrine Society's 2014 guideline on female androgen insufficiency states that "evidence is insufficient to support testosterone use in women for indications other than low libido," but acknowledges the metabolic monitoring need when it is prescribed off-label [14].

CGM Accuracy Considerations Specific to Women

Sensor Placement and Body Composition

Most CGM sensors are approved for placement on the posterior upper arm or abdomen. Women with lower subcutaneous arm fat depth may experience more motion artifact and slightly higher MARD. A 2020 study in Diabetes Technology and Therapeutics (N=80, 55% female) found no statistically significant sex difference in MARD for Libre 2, but did find that BMI <22 was associated with MARD 1.8 percentage points higher than BMI 22 to 30 [15]. Very lean women may see modestly less accurate readings.

Iron Deficiency and CGM Readings

Iron deficiency anemia, disproportionately common in premenopausal women due to menstrual blood loss, can affect CGM accuracy. Hemoglobin affects the optical properties of interstitial fluid, and some sensor chemistries have documented interference. Abbott's prescribing information for FreeStyle Libre 2 notes that severe anemia (hemoglobin <8 g/dL) may cause inaccurate readings. Clinicians should check CBC alongside CGM interpretation in women with heavy periods or low dietary iron.